Tscan Therapeutics To Present Updated Data From The Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session At The 66Th American Society Of Hematology Annual Meeting And Exposition
Tscan Therapeutics To Present Updated Data From The Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session At The 66Th American Society Of Hematology Annual Meeting And Exposition . (MENAFN - GlobeNewsWire - Nasdaq) To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108973600/Tscan-Therapeutics-To-Present-Updated-Data-From-The-Ongoing-ALLOHA™-Phase-1-Heme-Trial-During-Oral-Session-At-The-66Th-American-Society-Of-Hematology-Annual-Meeting-And-Exposition
2024-12-09
rss
(MENAFN - GlobeNewsWire - Nasdaq) To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; ...
Tscan Therapeutics To Present Updated Data From The Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session At The 66Th American Society Of Hematology Annual Meeting And Exposition